Boston Scientific lowers guidance amid cybersecurity fallout; investor investigation…
What happened
Bronstein, Gewirtz & Grossman, LLC has begun investigating potential claims for purchasers of Boston Scientific Corporation. This action follows the company's Q3 2026 financial report on October 28, 2026, during which Boston Scientific missed analyst consensus estimates for earnings per share. The company also lowered its sales and earnings guidance for the third consecutive quarter.
From pr-inside.com
Why it matters
Boston Scientific attributed the severe guidance revision to operational fallout and remediation costs resulting from a major cybersecurity incident, alongside structural challenges in its Watchman heart device and electrophysiology segments. Following the report, Boston Scientific's stock price fell 5.84% on October 28, 2026.
From pr-inside.com
Who's involved
- Boston ScientificWorldwide developer and manufacturer of medical devices
- AmundiFrench subsidiary that may be affected by the stock price drop
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- AmundiSpeculative
Amundi might see its investment position affected by the decline in Boston Scientific's stock price.
Keep exploring
The entities involved
-
Boston Scientific
worldwide developer, manufacturer and marketer of medical devices
-
New York City
most populous city in the United States
Related events
- A legal firm is operating in New York City involving the Greenland Energy Company.
- Fierce Pharma hosted its annual industry awards ceremony in New York City.
- Johnson & Johnson was referenced in a recent news report concerning New York City.
- Epic moved its headquarters to New York City on November 2, 2026.
- Lifetime Brands, Inc. hosted its Investor Day in New York City on October 1, 2026.